Inebilizumab Shows Lasting Protection Against NMOSD Attacks Regardless of Prior Immunosuppressant Use
A long-term analysis of the N-MOmentum trial shows inebilizumab reduces NMOSD attack risk and disability worsening equally well in patients ...
A long-term analysis of the N-MOmentum trial shows inebilizumab reduces NMOSD attack risk and disability worsening equally well in patients ...
A phase III trial of obinutuzumab β shows striking efficacy in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorder, deepening questions about which ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine